News | November 03, 2021
Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Acute therapies continue to report strong growth compared to chronic ones.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Subscribe To Our Newsletter & Stay Updated
